Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.51 USD | -0.75% | +3.67% | +25.11% |
Financials (USD)
Sales 2024 * | 27.96M | Sales 2025 * | 27.8M | Capitalization | 968M |
---|---|---|---|---|---|
Net income 2024 * | -228M | Net income 2025 * | -265M | EV / Sales 2024 * | 23.5 x |
Net cash position 2024 * | 311M | Net cash position 2025 * | 229M | EV / Sales 2025 * | 26.6 x |
P/E ratio 2024 * |
-4.28
x | P/E ratio 2025 * |
-4.06
x | Employees | 284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.44% |
Latest transcript on Bicycle Therapeutics plc
1 day | +0.49% | ||
1 week | +3.42% | ||
Current month | -8.92% | ||
1 month | -11.02% | ||
3 months | +27.99% | ||
6 months | +44.18% | ||
Current year | +25.44% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lee
CEO | Chief Executive Officer | 55 | 15-08-31 |
Alethia Young
DFI | Director of Finance/CFO | 45 | 23-07-16 |
Alistair Milnes
COO | Chief Operating Officer | 50 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pierre Legault
CHM | Chairman | 63 | 19-03-17 |
Director/Board Member | 61 | 21-03-16 | |
Richard Kender
BRD | Director/Board Member | 68 | 19-07-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 22.62 | -0.26% | 437 906 |
24-04-23 | 22.68 | +0.49% | 163,474 |
24-04-22 | 22.57 | -3.75% | 395,115 |
24-04-19 | 23.45 | -4.25% | 546,482 |
24-04-18 | 24.49 | +12.24% | 698,554 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.44% | 968M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+2.82% | 22.19B | |
-16.16% | 21.33B | |
-7.42% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- BCYC Stock